Harvard Physics Startup Launches with a Focus on Untouched Layer of the Atmosphere
The mesosphere holds untapped data helpful for understanding climate change, and the possibility of new communication networks.
Startup Formation
Create the future
Our team excels at convening extraordinary leaders who have the vision to bring transformative technologies to market. In just the past 5 years, 100+ startups have launched to commercialize Harvard innovations, collectively raising more than $4.4 billion in equity financing.
New companies are taking shape all the time. Take an early look at our emerging Startup Opportunities and join us in building ventures that could change the world.
Added value
Harvard faculty are preeminent scholars and prolific inventors. In OTD, we also understand that some academic innovations need a boost to succeed commercially.
OTD’s pioneering technology accelerator programs—the Blavatnik Biomedical Accelerator and the Harvard Grid Accelerator—help bridge the development gap, providing focused funding and resources to validate and de-risk promising technologies for successful partnering.
Deep connections
What ultimately makes it all work? Passionate people.
Our wide network of venture capitalists and entrepreneurs—many of whom are Harvard alumni—give generously of their time and expertise, leading and investing in new startup companies, engaging with labs as Entrepreneurs in Residence or Experts in Residence, serving on our accelerator advisory committees, speaking at OTD events, and making valuable connections throughout Cambridge and Boston.
Startup news
Four Harvard research teams receive translational funding to advance climate change tech
With funding and support from the Climate and Sustainability Translational Fund, researchers will pursue green jet fuel, cleaner chemicals, sustainable packaging, and carbon storage.
Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies
Attivare Therapeutics, a Harvard startup out of the Wyss Institute, has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS), Dana-Farber Cancer Institute, and Massachusetts General Hospital. This technology creates an in vivo training ground for the immune system to fight cancer more effectively and prevent infection.
Be the first to receive news & updates
Keep in touch with news and partnering opportunities from Harvard’s Office of Technology Development.